Teaser Bild
Hände halten Petrischalen im Labor

Global initiatives against antibiotic resistance

The fight against the "silent pandemic”
Teaser Text

Antibiotic-resistant bacteria are an increasing threat to global health. To counteract this danger, antibiotics should be used more sparingly, and new drugs should be developed. The German government is pursuing these goals with major international initiatives -– supported by the DLR Projektträger (DLR-PT).

Headline, Text + Image
Content Module Text

Antibiotics can be used to treat bacterial infections effectively. However, many bacteria are adaptable and develop resistance, and the drugs then lose their effect – a worldwide threat to many people.

As DLR-PT, we contribute to the global fight against antibiotic resistance with our technical and administrative expertise and tailored support for key decision-makers.

Cross-border research funding on antibiotic resistance, supported by DLR-PT

The German government is working in international bodies for greater cross-border cooperation to counteract the spread of antibiotic-resistant bacteria. Important goals include a more economical and responsible use of existing antibiotics and the development of new antibiotics or therapy alternatives.

During the German G20 presidency in 2017, the governments of the G20 countries agreed to jointly tackle these goals. DLR-PT supported the German government with research and innovation policy analyses during the negotiation and consultation processes.

Following the declaration by the G20 Leaders , the Global Antimicrobial Resistance Research & Development Hub (Global AMR R&D Hub) was launched.

With its technical and administrative expertise, DLR-PT assists the Federal Ministry of Education and Research (BMBF) in the conception and implementation of this global initiative.

Prepared with the help of DLR-PT – "Global AMR R&D Hub" collects and analyses worldwide knowledge

The Global AMR R&D Hub compiles information and knowledge on antibiotic resistance, provides analyses and uses them to develop recommendations for research policy makers. Based on this information and recommendations, the members of the Hub (17 nations, two foundations and the European Commission) make their decisions on which projects should be prioritised for funding and which incentive mechanisms should be set for the development of new antibiotics.

DLR-PT has been intensively supporting the BMBF since the founding phase of the Global AMR R&D Hub. Among other things, it has developed concepts, organised conferences and actively helped establish the Hub. Its secretariat, based in Berlin, has since been financed by the Federal Government – with technical and administrative support provided by DLR-PT.

International research projects on antibiotic resistance – DLR-PT supports Federal Ministry of Education and Research in JPIAMR

Assisted by DLR-PT, the BMBF is an active member of the “Joint Programming Initiative on Antimicrobial Resistance“ (JPIAMR). In this initiative, 28 nations as well as the European Commission are jointly addressing the most pressing issues in research into antibiotic resistance and are promoting multinational research projects. DLR-PT supports the BMBF in its many tasks, including work in committees of the international initiative and in the national implementation of the funding programmes initiated by the ministry within the framework of JPIAMR. In addition, DLR-PT is responsible for the funding management of the research projects.

Humans & animals – antibiotic resistance threatens both

The problem of antibiotic resistance in healthcare is closely linked to the use of antibiotics in animal husbandry and agriculture, as well as the presence of antibiotics in the environment. It is therefore important to consistently consider all these aspects together (the “One Health approach”). The experts at DLR-PT are engaging in technical and conceptual activities addressing this important topic.

Our contribution against a "silent pandemic

Our employees are committed to ensuring that the measures we initiate and supervise for our clients contribute to counteracting a "silent pandemic" and to protecting people's health.

Info box
Antibiotic resistance – an increasing danger

According to estimates, about 700,000 people worldwide are dying each year from infectious agents against which antibiotics are no longer effective. Without effective changes, this number could grow to ten million by 2050. ("Review on Antimicrobial Resistance")

Client Reference Box
Client Module Image
Bereichsicon Gesundheit
Main and Other Contacts

Contact at DLR Projektträger